Rapport Therapeutics (RAPP) Leases (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Leases data on record, last reported at $9.3 million in Q1 2026.
- On a quarterly basis, Leases rose 24.86% to $9.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.3 million, a 24.86% increase, with the full-year FY2025 number at $9.9 million, up 587.17% from a year prior.
- Leases reached $9.3 million in Q1 2026 per RAPP's latest filing, down from $9.9 million in the prior quarter.
- Over the last five years, Leases for RAPP hit a ceiling of $11.0 million in Q2 2025 and a floor of $1.4 million in Q4 2024.
- A 4-year average of $6.1 million and a median of $7.5 million in 2025 define the central range for Leases.
- Peak YoY movement for Leases: plummeted 30.81% in 2024, then soared 587.17% in 2025.
- Tracing RAPP's Leases over 4 years: stood at $2.1 million in 2023, then tumbled by 30.81% to $1.4 million in 2024, then skyrocketed by 587.17% to $9.9 million in 2025, then decreased by 5.87% to $9.3 million in 2026.
- Business Quant data shows Leases for RAPP at $9.3 million in Q1 2026, $9.9 million in Q4 2025, and $10.5 million in Q3 2025.